Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02268994 · ClinicalTrials.gov registry record · Phase 3
KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD
A Phase 3 study, sponsored by Keryx Biopharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 234
- Enrollment target
NCT02268994 is a Phase 3 study that has completed, run by Keryx Biopharmaceuticals. The registered enrollment target is 234 participants.
The verdict
NCT02268994, a Phase 3 study, has completed, sponsored by Keryx Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 234 participants
- Enrollment target
Study Summary
a 24-week phase 3, multi-center clinical trial, comprised of a 16-week, randomized, double-blind, placebo-controlled period ("Randomized Period"), followed by an 8-week open-label safety extension period, where all subjects receive KRX-0502 (ferric citrate) ("Extension Period").
Interventions
- DRUG Placebo
- DRUG ferric citrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 234 participants |
| Start Date | 2014-10 |
| Est. Completion | 2016-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02268994
The ClinicalTrials.gov registry entry for NCT02268994 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 234 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Keryx Biopharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02268994 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02268994 about?
NCT02268994 is a clinical study titled "KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD". a 24-week phase 3, multi-center clinical trial, comprised of a 16-week, randomized, double-blind, placebo-controlled period ("Randomized Period"), followed by an 8-week open-label safety extension period, where all subjects receive KRX-0502 (ferric citrate) ("Extension Period").
What is the current status of trial NCT02268994?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 234 participants. The study started on 2014-10. Estimated completion is 2016-01.
What interventions are being tested in trial NCT02268994?
The interventions under investigation include: Placebo (DRUG), ferric citrate (DRUG).
Who is sponsoring clinical trial NCT02268994?
This trial is sponsored by Keryx Biopharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.